Daiichi Sankyo Company Management

Management criteria checks 3/4

Daiichi Sankyo Company's CEO is Sunao Manabe, appointed in Jun 2019, has a tenure of 4.92 years. total yearly compensation is ¥401.00M, comprised of 26.9% salary and 73.1% bonuses, including company stock and options. directly owns 0.008% of the company’s shares, worth ¥824.83M. The average tenure of the management team and the board of directors is 3.1 years and 3.9 years respectively.

Key information

Sunao Manabe

Chief executive officer

JP¥401.0m

Total compensation

CEO salary percentage	26.9%
CEO tenure	4.9yrs
CEO ownership	0.008%
Management average tenure	3.1yrs
Board average tenure	3.9yrs

Recent management updates

Recent updates

Here's Why Daiichi Sankyo Company (TSE:4568) Has Caught The Eye Of Investors

May 22

Statutory Profit Doesn't Reflect How Good Daiichi Sankyo Company's (TSE:4568) Earnings Are

May 02

Daiichi Sankyo Company, Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Apr 27

Daiichi Sankyo Company (TSE:4568) Is Paying Out A Larger Dividend Than Last Year

Mar 11

Daiichi Sankyo Company (TSE:4568) Will Pay A Larger Dividend Than Last Year At ¥30.00

Feb 26

CEO Compensation Analysis

How has Sunao Manabe's remuneration changed compared to Daiichi Sankyo Company's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	JP¥201b
Dec 31 2023	n/a	n/a	JP¥186b
Sep 30 2023	n/a	n/a	JP¥148b
Jun 30 2023	n/a	n/a	JP¥147b
Mar 31 2023	JP¥401m	JP¥108m	JP¥109b
Dec 31 2022	n/a	n/a	JP¥59b
Sep 30 2022	n/a	n/a	JP¥63b
Jun 30 2022	n/a	n/a	JP¥51b
Mar 31 2022	JP¥341m	JP¥108m	JP¥67b
Dec 31 2021	n/a	n/a	JP¥94b
Sep 30 2021	n/a	n/a	JP¥87b
Jun 30 2021	n/a	n/a	JP¥79b
Mar 31 2021	JP¥170m	JP¥99m	JP¥76b
Dec 31 2020	n/a	n/a	JP¥71b
Sep 30 2020	n/a	n/a	JP¥116b
Jun 30 2020	n/a	n/a	JP¥118b
Mar 31 2020	JP¥197m	JP¥97m	JP¥129b
Dec 31 2019	n/a	n/a	JP¥149b
Sep 30 2019	n/a	n/a	JP¥114b
Jun 30 2019	n/a	n/a	JP¥113b
Mar 31 2019	JP¥165m	JP¥90m	JP¥93b

Compensation vs Market: Sunao's total compensation ($USD2.56M) is above average for companies of similar size in the JP market ($USD1.61M).

Compensation vs Earnings: Sunao's compensation has been consistent with company performance over the past year.

CEO

Sunao Manabe (69 yo)

4.9yrs

Tenure

JP¥401,000,000

Compensation

Mr. Sunao Manabe, D.V.M, Ph D., had been President of Daiichi Sankyo Company, Limited since April 1, 2017 until April 01, 2023 and serves as its Chief Executive Officer since June 17, 2019 and serves as it...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Sunao Manabe	Group CEO & Executive Chairperson	4.9yrs	JP¥401.00m	0.0079% ¥ 835.5m
Hiroyuki Okuzawa	President	1.1yrs	JP¥151.00m	0.0021% ¥ 220.2m
Shoji Hirashima	Senior Managing Executive Officer	5.1yrs	JP¥166.00m	0.0036% ¥ 379.3m
Koji Ogawa	Managing Executive Officer	7.1yrs	no data	no data
N/A Chiyu	General Manager of Finance & Accounting Department	no data	no data	no data
Hiroto Kashiwase	Managing Executive Officer & Head of Technology Division	no data	no data	no data
Naoto Tsukaguchi	Gen. Counsel	no data	no data	no data
Matt Allegrucci	Head of Global Compliance & Risk Management and Chief Compliance Officer	less than a year	no data	no data
Kentaro Asakura	Vice President of Corporate Communications Department	no data	no data	no data
Marielle Cohard-Radice	Global Head of Development	no data	no data	no data
Akio Sakurai	Corporate Officer	3.1yrs	no data	no data
Takashi Matsumoto	Managing Executive Officer	2.3yrs	no data	no data

3.1yrs

Average Tenure

62yo

Average Age

Experienced Management: 4568's management team is considered experienced (3.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Sunao Manabe	Group CEO & Executive Chairperson	9.9yrs	JP¥401.00m	0.0079% ¥ 835.5m
Hiroyuki Okuzawa	President	2.9yrs	JP¥151.00m	0.0021% ¥ 220.2m
Shoji Hirashima	Senior Managing Executive Officer	3.9yrs	JP¥166.00m	0.0036% ¥ 379.3m
Takashi Fukuoka	Senior Managing Exec. Officer	1.9yrs	no data	0.00073% ¥ 76.9m
Kazuaki Kama	Independent Outside Chairperson	4.9yrs	no data	0.00021% ¥ 22.1m
Takaaki Nishii	Independent Outside Director	less than a year	no data	0.000050% ¥ 5.3m
Masahiko Ohtsuki	Director	3.9yrs	JP¥153.00m	0.0031% ¥ 329.8m
Sawako Nohara	Independent Outside Director	4.9yrs	no data	0.000050% ¥ 5.3m
Miyuki Arai	Member of Audit & Supervisory Board	less than a year	no data	0.0010% ¥ 109.6m
Kenji Sato	Chairman of Audit & Supervisory Board	4.9yrs	no data	0.0013% ¥ 131.7m
Yukiko Imazu	Outside Audit & Supervisory Board Member	5.9yrs	no data	no data
Yasuhiro Komatsu	Independent Outside Director	1.9yrs	no data	no data

3.9yrs

Average Tenure

63yo

Average Age

Experienced Board: 4568's board of directors are considered experienced (3.9 years average tenure).

Daiichi Sankyo Company Management

Management criteria checks 3/4

Key information

Recent management updates

Daiichi Sankyo Company, Limited, Annual General Meeting, Jun 17, 2024

Recent updates

Here's Why Daiichi Sankyo Company (TSE:4568) Has Caught The Eye Of Investors

Statutory Profit Doesn't Reflect How Good Daiichi Sankyo Company's (TSE:4568) Earnings Are

Investor sentiment improves as stock rises 15%

AstraZeneca PLC and Daiichi Sankyo Announces ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Improved PFS in HER2-Low and Ultralow

Now 27% overvalued after recent price rise

Daiichi Sankyo Company, Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Daiichi Sankyo Company, Limited (TSE:4568) announces an Equity Buyback for 55,000,000 shares, representing 2.87% for ¥200,000 million.

Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer

Daiichi Sankyo Company, Limited, Annual General Meeting, Jun 17, 2024

Upcoming dividend of JP¥30.00 per share

Daiichi Sankyo Company (TSE:4568) Is Paying Out A Larger Dividend Than Last Year

The European Medicines Agency Validates Two Marketing Authorization Applications for Daiichi Sankyo and AstraZeneca

Daiichi Sankyo Company, Limited to Report Fiscal Year 2024 Results on Apr 25, 2024

Consensus EPS estimates increase by 10%

Daiichi Sankyo Company (TSE:4568) Will Pay A Larger Dividend Than Last Year At ¥30.00

AstraZeneca and Daiichi Sankyo's Biologics License Application for Datopotamab Deruxtecan Accepted in the US

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Daiichi Sankyo Company, Limited Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024

Daiichi Sankyo Company, Limited Revises Dividend Guidance for the Year Ending March 31, 2024

Daiichi Sankyo and AstraZeneca Announces Two Phase 3 Trials of Datopotamab

Daiichi Sankyo Company, Limited to Report Q3, 2024 Results on Jan 31, 2024

Daiichi Sankyo Company, Limited Appeals Amended Texas Court Judgement in Patent Dispute with Seagen Inc

IHH Healthcare Berhad Announces Update on Claim Before the Tokyo District Court in Japan by NTK Against Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited's VANFLYTA (quizartinib) Approves in the EU as the First FLT3 Inhibitor Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Astrazeneca and Daiichi Sankyo Announces Positive Results from the Pivotal Tropion-Breast01 Phase Iii Trial

Daiichi Sankyo and Astrazeneca’S Enhertu Demonstrated Clinically Meaningful Survival Across Multiple Her2 Expressing Advanced Solid Tumors in Destiny-Pantumor02 Phase 2 Trial

Daiichi Sankyo and Astrazeneca Announce Datopotamab Deruxtecan Plus Durvalumab Demonstrated Robust and Durable Tumor Responses in First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer in BEGONIA Phase 1b/2 Trial

Daiichi Sankyo and AstraZeneca Announce Datopotamab Deruxtecan Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival Benefit in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial

Upcoming dividend of JP¥17.00 per share at 0.9% yield

European Union Recommends ENHERTU for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer

Daiichi Sankyo Company, Limited and AstraZeneca PLC Announce Datopotamab Deruxtecan Plus Durvalumab Showed Promising Clinical Activity in the First-Line Advanced Non-Small Cell Lung Cancer Setting in TROPION-Lung04 Phase 1b Trial

Daiichi Sankyo Announces First Patient Dosed in a First-In-Human Phase 1/2 Trial Evaluating DS-3939 in Patients with Several Types of Advanced Solid Cancers

Daiichi Sankyo Company, Limited's ENHERTU Receives Two Breakthrough Therapy Designations in U.S. for Patients Across Multiple HER2 Expressing Cancers

Daiichi Sankyo Company, Limited to Report Q2, 2024 Results on Oct 31, 2023

Daiichi Sankyo Company, Limited Announces Vanflyta® Now Available in U.S. for Patients with Newly Diagnosed FLT3-ITD Positive AML

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Daiichi Sankyo Company, Limited and AstraZeneca PLC Reports ENHERTU Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial

Daiichi Sankyo Company, Limited and AstraZeneca PLC Reports ENHERTU Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial

Daiichi Sankyo Company, Limited Announces FDA Approves VANFLYTA (Quizartinib) in Combination with Standard Cytarabine and Antibody Indication

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age